Renin angiotensin system inhibitors may attenuate low LDL cholesterol-related cancer risk in type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 5, 2014, Pages 415-423

  Yang, Xilin ^a,c   Ma, Ronald C W ^a,b   So, Wing Yee ^a,b   Wang, Ying ^a,b   Kong, Alice P S ^a,b   Ozaki, Risa ^a,b   Xu, Gang ^a,b   Chan, Juliana C N ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Additive interaction; Albuminuria; Cancer; Low LDL cholesterol; Low triglyceride; RAS inhibitors; Type 2 diabetes

Indexed keywords

ANGIOTENSIN II; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM INHIBITOR; RENIN INHIBITOR; SOMATOMEDIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALBUMINURIA; ARTICLE; CANCER PREVENTION; CANCER RISK; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR INTERACTION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; BLOOD; COHORT ANALYSIS; COMPLICATION; DRUG EFFECTS; NEOPLASMS; PROSPECTIVE STUDY; REGISTER; RISK;

AGED; ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; REGISTRIES; RENIN-ANGIOTENSIN SYSTEM; RISK; TRIGLYCERIDES;

EID: 84903702976     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2504     Document Type: Article

References (36)

1. Yang X, So WY, Ma RC, Kong AP, Xu G, Chan JC. Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. Diabetes Metab Res Rev 2012; 28(5): 379-387.
2. Yang X, So WY, Ma RC, et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011; 34(2): 375-380.
3. Yang X, So WY, Ma RC, et al. Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Care 2009; 32(10): 1826-1832.
4. Yang X, So WY, Ma RC, et al. Synergistic effects of low LDL cholesterol with other factors for the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Acta Diabetol 2012; 49(Suppl 1): 185-193.
5. Yang X, So W, Ko GT, et al. Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 2008; 179(5): 427-437.
6. Singh BM, Mehta JL. Interactions between the renin-angiotensin system and dyslipidemia: relevance in the therapy of hypertension and coronary heart disease. Arch Intern Med 2003; 163(11): 1296-1304.
7. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89(3): 331-340.
8. Jia G, Aggarwal A, Yohannes A, Gangahar DM, Agrawal DK. Cross-talk between angiotensin II and IGF-1-induced connexin 43 expression in human saphenous vein smooth muscle cells. J Cell Mol Med 2011; 15(8): 1695-1702.
9. Shimomura I, Bashmakov Y, Ikemoto S, Horton JD, Brown MS, Goldstein JL. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A 1999; 96(24): 13656-13661.
10. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008; 128(5): 1286-1293.
11. Muller C, Reddert A, Wassmann S, Strehlow K, Bohm M, Nickenig G. Insulin-like growth factor induces up-regulation of AT(1)-receptor gene expression in vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst 2000; 1(3): 273-277.
12. van Eickels M, Vetter H, Grohe C. Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation. Br J Pharmacol 2000; 131(8): 1592-1596.
13. Yang X, Zhao H, Sui Y, et al. Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 2009; 58(7): 1518-1525.
14. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M. For the DiabCare Monitoring Group of the St. Vincent Declaration Steering Committee. Monitoring the targets of the St. Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabetic Med 1993; 10: 371-377.
15. Laakso M, Pyorala K. Age of onset and type of diabetes. Diabetes Care 1985; 8(2): 114-117.
16. Yang X, So WY, Tong PC, et al. Development and validation of an all-cause mortality risk score in type 2 diabetes. Arch Intern Med 2008; 168(5): 451-457.
17. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17(10): 2937-2944.
18. Wolkewitz M, Allignol A, Harbarth S, de Angelis G, Schumacher M, Beyersmann J. Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. J Clin Epidemiol 2012; 65(11): 1171-1180.
19. Kiri VA, Mackenzie G. Re: "Immortal time bias in pharmacoepidemiology". Am J Epidemiol 2009; 170(5): 667-668; author reply 8-9.
20. Yang X, Kong AP, Luk AO, et al. Validation of methods to control for immortal time bias in pharmacoepidemiological analysis of renin-angiotensin system inhibitors in Type 2 diabetes. J Epidemiol 2014; 24(3) (in press).
21. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. Eur J Epidemiol 2005; 20(7): 575-579.
22. Yang X, So WY, Ma RC, et al. Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer 2008; 15(2): 597-607.
23. Yang X, Ko GT, So WY, et al. Associations of hyperglycaemia and insulin usage with the risk of cancer in Type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes 2010; 59(5): 1254-1260.
24. Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how? Diabetes Obes Metab 2012; 14(7): 579-585.
25. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 2007; 6(10): 821-833.
26. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010; 10(11): 745-759.
27. Yasumaru M, Tsuji S, Tsujii M, et al. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res 2003; 63(20): 6726-6734.
28. Lindholm LH, Carlberg B. Blood-pressure drugs and cancer: much ado about nothing? Lancet Oncol 2010; 12(1): 6-8.
29. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352(9123): 179-184.
30. Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ 2011; 183(14): E1073-E1084.
31. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials. Lancet Oncol 2010; 12(1): 65-82.
32. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138, 769 individuals. J Hypertens 2011; 29(4): 623-635.
33. Sugimoto M, Yamaoka Y, Shirai N, Furuta T. Role of renin-angiotensin system in gastric oncogenesis. J Gastroenterol Hepatol 2012; 27(3): 442-451.
34. Kubota M, Shimizu M, Sakai H, et al. Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Biochem Biophys Res Commun 2011; 410(1): 108-113.
35. Zahradka P, Litchie B, Storie B, Helwer G. Transactivation of the insulin-like growth factor-I receptor by angiotensin II mediates downstream signaling from the angiotensin II type 1 receptor to phosphatidylinositol 3-kinase. Endocrinology 2004; 145(6): 2978-2987.
36. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301(20): 2129-2140.